Daxor Co. (NASDAQ:DXR – Get Free Report) was the recipient of a large increase in short interest in the month of September. As of September 30th, there was short interest totalling 15,900 shares, an increase of 7.4% from the September 15th total of 14,800 shares. Based on an average daily volume of 5,500 shares, the short-interest ratio is presently 2.9 days. Approximately 0.8% of the shares of the stock are short sold.
Analysts Set New Price Targets
Separately, Ascendiant Capital Markets boosted their price target on shares of Daxor from $24.50 to $24.75 and gave the company a “buy” rating in a research report on Monday, September 9th.
Daxor Stock Up 1.4 %
About Daxor
Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.
Read More
- Five stocks we like better than Daxor
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- The How and Why of Investing in Gold Stocks
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is Short Interest? How to Use It
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.
